Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
EFCAB2-AS1 is a predicted long non-coding antisense RNA transcribed from the EFCAB2 locus. Antisense transcripts like EFCAB2-AS1 are typically non-protein-coding and may regulate their corresponding sense gene (EFCAB2) post-transcriptionally or transcriptionally by mechanisms observed with other natural antisense transcripts, such as modulating mRNA stability or translation[2]. However, there is currently no direct experimental evidence regarding the specific function, biological role, clinical relevance, or disease association for EFCAB2-AS1 itself. No drugs or therapeutics are known to interact with or target this transcript, and it is not regarded as a classical receptor, enzyme, or therapeutic target. The sense gene, EFCAB2, encodes a testis-specific calcium-binding protein with two EF-hand motifs and is involved in calcium signaling within sperm cells[1]. Antisense long non-coding RNAs (as a class) often participate in gene regulation but require experimental validation for each member[2]. RP11-156E8.1 is the Ensembl/Gencode accession for this lncRNA transcript and refers to the same entity. If interest involves protein targets, EFCAB2 (not the antisense transcript) would be the calcium-binding protein[1]. EFCAB2-AS1 does not fit criteria for being a canonical therapeutic receptor, enzyme, or transporter and is best classified as a predicted natural antisense long non-coding RNA. There is no direct evidence for it as a drug target or biomarker at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on EFCAB2 antisense RNA 1 (EFCAB2-AS1).